SEC Form 4 · accession 0001240679-17-000035
PSYCHEMEDICS CORP · PMD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael I Schaffer
Officer — VP of Laboratory Operations
Period of report
Sep 1, 2017
Accepted (ET)
Sep 6, 2017 · 4:34 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000806517
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $.005 Par ValueF1 | Sep 1, 2017 | S | 981 | $21.16 | D | 41,273 | D | |
| Common Stock, $.005 Par ValueF2 | Sep 5, 2017 | S | 4,400 | $20.37 | D | 36,873 | D | |
| Common Stock, $.005 Par ValueF3 | Sep 6, 2017 | S | 2,167 | $20.14 | D | 34,706 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.00 to $21.22, inclusive. The reporting person undertakes to provide to Psychemedics Corp., any security holder of Psychemedics Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
- F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.26 to $20.54, inclusive. The reporting person undertakes to provide to Psychemedics Corp., any security holder of Psychemedics Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
- F3Includes an additional 188 shares acquired since May 23, 2017 under the Company's Dividend Reinvestment Plan.